CervoMed (CervoMed) Growth Rank : 0 (As of Jun. 04, 2024)

View and export this data going back to 1996. Start your Free Trial

What is CervoMed Growth Rank?

CervoMed has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

CervoMed Growth Rank Related Terms

Thank you for viewing the detailed overview of CervoMed's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

CervoMed (CervoMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CervoMed Inc (NAS:CRVO) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Park Plaza, Suite 424, Boston, MA, USA, 02216

Website

https://www.diffusionpharma.com

CervoMed Inc Formerly Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Geographically business activity of the firm functions through the region of the United States.

Executives

Frank Zavrl	director	C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Sylvie Gregoire	director, 10 percent owner	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
John William Tanner	officer: Chief Financial Officer	C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116
Kelly Blackburn	officer: VP, Clinical Development	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marwan Sabbagh	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
John J Alam	director, 10 percent owner, officer: CEO and President	130 WAVERLY STREET, CAMBRIDGE MA 02139
Jeffrey V. Poulton	director	300 THIRD STREET, CAMBRIDGE MA 02142
Jill Davidson	director	300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902
Raven Jaeger	officer: Chief Regulatory Officer	300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902
Eric Francois	director	C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Diana M Lanchoney	director	1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902
William Robert Elder	officer: GC & Secretary	1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Cobuzzi Robert Joseph Jr.	director	C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Christopher D Galloway	officer: Chief Medical Officer	1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Jane H Hollingsworth	director	DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902